Biomarin Pharmaceutical Inc. (BMRN): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Biomarin Pharmaceutical ( BMRN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.1%. By the end of trading, Biomarin Pharmaceutical rose $1.34 (1.9%) to $70.80 on heavy volume. Throughout the day, 1,558,983 shares of Biomarin Pharmaceutical exchanged hands as compared to its average daily volume of 1,016,000 shares. The stock ranged in a price between $69.48-$70.85 after having opened the day at $69.55 as compared to the previous trading day's close of $69.46. Other companies within the Drugs industry that increased today were: GW Pharmaceuticals PLC ADR ( GWPH), up 89.3%, Rockwell Medical ( RMTI), up 32.5%, Echo Therapeutics ( ECTE), up 12.9% and Portola Pharmaceuticals ( PTLA), up 12.6%.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Biomarin Pharmaceutical has a market cap of $9.5 billion and is part of the health care sector. Shares are up 41.2% year to date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Biomarin Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and feeble growth in the company's earnings per share.

On the negative front, Agenus ( AGEN), down 23.4%, Genvec ( GNVC), down 10.4%, Vivus ( VVUS), down 8.9% and China Pharma ( CPHI), down 8.5% , were all laggards within the drugs industry with Biogen Idec ( BIIB) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.